Cellectis S.A.

Equities

ALCLS

FR0010425595

Biotechnology & Medical Research

Real-time Euronext Paris Other stock markets 11:35:18 2024-07-17 EDT			5-day change	1st Jan Change
1.868 ^EUR	-1.58%		+9.50%	-32.42%

07-16	Nicox appoints new Chairman of the Board of Directors	CF
07-12	European Equities Traded in the US as American Depositary Receipts Climb Higher in Friday Trading	MT

Cellectis Mulls IPO

January 08, 2015 at 12:00 am

Cellectis (ENXTPA:ALCLS) announced that it plans to conduct a registered initial public offering (IPO) in the United States. The timing, number of shares and price of the proposed offering have not yet been determined.

Latest news about Cellectis S.A.

Nicox appoints new Chairman of the Board of Directors	07-16	CF
European Equities Traded in the US as American Depositary Receipts Climb Higher in Friday Trading	07-12	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading	07-10	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading	07-09	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading	07-03	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading	07-02	MT
European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading	06-27	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	06-26	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower Friday But End Week Higher	06-21	MT
European Equities Traded in the US as American Depositary Receipts Move Higher in Thursday Trading	06-20	MT
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Tuesday Trading	06-18	MT
Bank Stocks Help Nudge European Equities Traded in the US as American Depositary Receipts Higher in Monday Trading	06-17	MT
European Equities Traded in the US as American Depositary Receipts Fall Sharply in Friday Trading	06-14	MT
European Equities Traded in the US as American Depositary Receipts Sharply Lower in Thursday Trading	06-13	MT
Cellectis Announces the Publication of A Scientific Article in Nature Communications	06-12	CI
European Equities Traded in the US as American Depositary Receipts Rise Sharply in Wednesday Trading	06-12	MT
Oppenheimer Trims Cellectis Price Target to $10 From $11, Maintains Outperform Rating	06-12	MT
European Equities Traded in the US as American Depositary Receipts Trend Sharply Lower in Tuesday Trading	06-11	MT
European Equities Traded in the US as American Depositary Receipts Lower in Monday Trading	06-10	MT
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading	06-07	MT
Tech Firms Lead European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading	06-06	MT
European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading	06-05	MT
Cellectis: orphan drug designation in ALL	06-05	CF
Cellectis Gets Orphan Drug Label From European Commission For Acute Lymphoblastic Leukemia	06-04	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading	06-04	MT

Chart Cellectis S.A.

Duration

Period

More charts

Company Profile

Cellectis S.A. is a clinical-stage biotechnology company using its pioneering TALEN® genome-editing technology to develop innovative therapies for the treatment of serious diseases. Cellectis S.A. is developing the first CAR-T cell-based allogeneic immunotherapy therapeutics, inventing the concept of off-the-shelf, ready-to-use engineered CAR-T cells for the treatment of cancer patients, and a platform for performing therapeutic genetic modifications in hematopoietic stem cells in a various diseases. Capitalizing on its 23 years of expertise in genome engineering, its TALEN® genome editing technology and its pioneering PulseAgile electroporation technology, Cellectis S.A. is developing innovative product candidates using the power of the immune system to treat diseases with unmet medical needs. As part of its commitment to the search for curative cancer therapies, Cellectis S.A. is developing UCART product candidates directed at the unmet medical needs of patients with certain types of cancer, including acute myeloid leukemia, B-cell acute lymphoblastic leukemia, and multiple myeloma. HEAL is a new platform focused on hematopoietic stem cells for the treatment of blood disorders, immune deficiencies, and lysosomal storage diseases.

Sector

Biotechnology & Medical Research

Calendar

2024-07-31 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Cellectis S.A.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CELLECTIS S.A.	-32.42%	149M
MODERNA, INC.	+21.43%	47.96B
IQVIA HOLDINGS INC.	+1.40%	42.45B
LONZA GROUP AG	+43.85%	41.47B
ALNYLAM PHARMACEUTICALS, INC.	+26.97%	31.6B
ICON PUBLIC LIMITED COMPANY	+21.16%	28.63B
CELLTRION, INC.	-4.47%	28.03B
UNITED THERAPEUTICS CORPORATION	+52.57%	14.56B
MEDPACE HOLDINGS, INC.	+44.73%	14.14B
BIO-TECHNE CORPORATION	+3.05%	12.58B

Other Biotechnology & Medical Research